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ABSTRACT
Objective: To examine the genetic variability of Estonian Parkinson´s disease (PD) patients using 
an ongoing epidemiological study in combination with a genetic analysis.
Methods: This study was a community-based genetic screening study of 189 PD patients and 158 
age and sex matched controls screened for potential mutations in 9 PD genes using next-
generation sequencing and multiplex ligation-dependent probe amplification method. Different 
clinimetric scales and questionnaires were used to examine PD patients and assess clinical 
characteristics and severity of the disease.
Results: The overall frequency of pathogenic PD-causing variants was 1.1% (2/189), any rare 
genetic variant was present in 21.2% (40/189) of the patients and in 8.2% (13/158) of the 
controls (p<0.05). Variants of unknown significance accounted for 10.6% (20/189). Frequency of 
any GBA variant among PD patients was 10.1% (19/189) and in controls 3.8% (6/158). The 
frequency of any GBA variant in PD compared to controls was significantly higher (p = 0.035; OR 
2.82; CI 95% 1.05-8.87). Burden of rare variants was not different between patients and controls. 
Also, a novel GBA pathogenic variant p.E10X was detected.
Conclusion: Among different genetic variants identified in Estonian PD patients, GBA variants are 
the most common while an overall pathogenic variant frequency was 1.1%.
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Introduction
Parkinson´s disease (PD) is the second most common neurodegenerative disease with a global 
crude prevalence of 2-3% in people ≥65 years of age.1 Although mostly thought to be caused by a 
combination of environmental and genetic risk factors, about 15% of the patients have positive 
family history and 5-10% have a specific monogenetic form with Mendelian inheritance.2
The first PD related gene, -synuclein, was discovered in 19973 and ever since at least 19 disease 
causing genes and 23 loci have been reported. In addition, genome wide associations studies 
have detected multiple genes and loci that increase the risk of PD.4 Estonia lies in the North-
Eastern part of Europe and has a population of about 1.3 million. The age-adjusted prevalence of 
PD is 314/100 0005 so there are about 4000 PD patients in Estonia.
Native Europeans, in general, are genetically relatively homogenous, but still have a northwest to 
southeast gradient in genetic diversity that correlates with geography.6
The genetic structure of North-Eastern Europeans has been well described and reveals that 
Estonians cluster together with their neighbours Latvians and Lithuanians, as well as with 
Western Russians and Poles, leaving the Finnish population to a separate cluster.7 At the same 
time, there are intra-population differences, with South-Eastern Estonians being genetically very 
close to Latvians, whereas Northern Estonians share more with Southern Finns.8
This study implemented a community-based approach to examine the genetic variability of 
Estonian PD patients, gathering data from an ongoing PD epidemiological study combined with 
genetic analysis. A gene panel was designed in the University College London´s Institute of 
Neurology, and included already established PD-causing genes as well as more recently PD-linked 
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Methods
Subjects
The current study was a community-based genetic screening study. Cases consisted of 189 PD 
patients of Estonian descent who had been previously diagnosed according to the Queen Square 
Brain Bank (QSBB) criteria11 and treated in the Tartu University Hospital´s Neurology Clinic. The 
patients enrolled in this study were also a part of the larger cross-sectional study that aimed to 
evaluate the prevalence and incidence of PD in Estonia.5 22 patients had a positive family history 
for PD in a first degree relative, and 9 patients in a distant relative. Early onset PD was defined by 
the age of onset below 50 years.
Comparison was made with 158 age and sex matched controls of the Estonian descent. The 
controls were recruited from the Tartu University Hospital´s Neurology Outpatient Clinic, and 
comprised of patients without any known central nervous system disease. All participants 
reported “white” ethnicity.
The following clinimetric scales were used to assess PD patients: the Movement Disorders 
Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)12, the Hoehn and Yahr Scale 
(HY)13, the Schwab and England Activities of Daily Living Scale (SE-ADL)14, the Beck Depression 
Inventory (BDI)15 and the Mini Mental State Examination (MMSE).16 Disease subtypes were based 
upon the most prevalent symptom during a standard neurological examination: tremor; 
bradykinesia-hypokinesia; or postural instability gait disorder (PIGD).
The study was approved by the Research Ethics Committee of the University of Tartu. A written 
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Genetic analysis
A pathogenic variant was defined as a variant that has been previously shown to be causative for 
autosomal dominant or recessive PD or to be an established risk allele for PD. A novel pathogenic 
variant was defined as a previously unreported loss-of-function variant in a gene for which loss-
of-function is an established mechanism.
Peripheral blood was obtained from PD patients and controls. Genomic DNA (gDNA) was 
extracted from the whole blood by the salting out protocol.17 
Both PD patients and controls were screened for potential mutations across 117 exons in 9 PD 
genes using next-generation sequencing (NGS) with Illumina´s MiSeq sequencer and polymerase 
chain reaction (PCR) amplicon-based (TruSeq custom amplicon) target enrichment. TruSeq 
custom amplicon assay Design Studio v1.6 online was used to design the probes. The assay was 
performed following the manufacturer´s recommended protocol. Exons not covered at all by at 
least 10 reads (PRK7/DJ1, PINK1, GBA, PRKN/PARK2, LRRK2 and GCH1) were subsequently Sanger 
sequenced. Variants with minor allele frequency (MAF) ≥ 1% in general population according to 
1000 Genome Project (www.1000genomes.org) were excluded from the analysis. PCR primers 
and conditions are available upon request.
All familial and early onset PD cases were screened by multiplex ligation-dependent probe 
amplification (MLPA) method looking for duplication and triplication of SNCA, copy number 
variations (CNVs) in PRKN, PRK7, PINK1 and point mutation in LRRK2 G2019S and SNCA A30P. 
Copy number variations were also looked for in carriers of heterozygous missense mutations in 
recessive genes. The P051-C3 Salsa MLPA Parkinson probe set was used (MRC Holland, 
Amsterdam, the Netherlands). Data were analyzed using Genemarker, version 2.6.2, software.
91.3% of the exons were completely covered by at least 10 reads. 1.7% of the exons were 
covered for the 50-99% by at least 10 reads. 7% of the exons failed (not covered at all by at least 
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Statistical analysis was conducted using R software (version 1.1.383). The level of significance 
was set to 0.05. Fisher exact test was used for comparing variation frequencies between PD 
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Results
A total of 189 patients with PD (113 women, 76 men) and 158 controls (96 women, 62 men) 
comprised the study group. The descriptive statistics of the clinimetric scales, the data on the 
clinical subtypes and the family history of PD patients are shown in Table 1.
The mean age of PD patients and controls at examination were 72.5±8.4 years (range 47-87) and 
72.0±9.1 years (range 47-95), respectively. The mean age at PD onset was 65.2 ±10.1 years 
(range 35-83), and the duration of PD 7.3 ±5.6 years (range 0.3-35). 17 early onset PD cases were 
identified including 3 cases with PD onset before 40 years. Any rare genetic variant was present 
in 21.2% (40/189) of the patients and in 8.2% (13/158) of the controls. Of all the rare variants 
detected in PD patients, the frequency of pathogenic PD-causing variants was 1.1% (2/189), both 
patients were carriers of single mutations in a recessive gene and had negative MLPA. The 
frequency of GBA-related risk variants was 9.5% (18/189) and variants on unknown significance 
accounted for 10.6% (20/189).
Three patients carried more than one variant: first patient carried three different variants in GBA, 
PRK7 and PINK1, another patient had two different variants in GBA and GHC1, and one patient 
had also two different variants in GBA and PRK7.
Three different pathogenic variants were identified in four PD patients: two patients carried a 
single heterozygous pathogenic variant in PRKN, one patient was a carrier of Gaucher´s disease 
causing variant in GBA, and another patient carried a novel pathogenic variant in GBA.
Out of all patients with a positive family history (PD in 22 first degree relatives and in 9 distant 
relatives), only five patients carried rare risk variants or variants with unknown significance, and 
no one carried pathogenic variants.
No duplication or triplication of SNCA, copy number variations in PRKN, PRK7, PINK1 and point 
mutation in LRRK2 G2019S and SNCA A30P were detected. No variants in DCTN1 were found. No 
cases with homozygous or compound heterozygous mutations in recessive genes (PRKN, PINK1, 
PRK7) were identified.
Summary of the genetic findings is presented in Table 2 and the frequencies of rare variants are 
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GBA
Five different variants were identified in the GBA gene. Frequency of any GBA variant among PD 
patients was 10.1% (19/189, MAF 0.05) and in controls 3.8% (6/158, MAF 0.018). The frequency 
of any GBA variant in PD compared to controls was significantly higher than in controls (p = 
0.035; OR 2.82; CI 95% 1.05-8.87). Novel or pathogenic mutations were found in three patients 
and in none of the controls. A novel GBA pathogenic variant p.E10X is likely to result in 
haploinsufficiency. Also, a novel variant of unknown significance p.L276I was detected in one 
patient and one patient carried a pathogenic variant L444P that in homozygous state causes 
severe form of Gaucher´s disease (types 2 and 3).
The difference between PD and controls was not significant for GBA common risk factors (T369M 
and E326K) for PD, however compared to other Caucasian controls there is an excess of T369M 
in PD cases (MAF=0.0265 in the Estonian cohort versus MAF=0.011 in a recent meta-analysis18).
GCH1
Two different variants were identified in PD patients only (p.V204I in two and p.Q110E in one PD 
patient), reported in detail elsewhere.19
LRRK2
Three different variants were found in the LRRK2 gene. The frequency of any LRRK2 variant was 
3.7% (7/189) among PD patients and 2.5% (4/158) in controls. No p.G2019S was detected in early 
onset or familial PD. Two patients and one control carried the variant p.E334K, four patients and 
three controls carried the variant p.R1514Q and the variant p.R767H was found in one patient 
only. 23 PD patients had the variant p.P1542S (MAF 0.06) but it was present at similar frequency 
in controls. However, for Estonian PD patients vs Caucasian controls the OR is 1.8. Overall, 
burden of rare variants did not differ between PD patients and controls.
VPS35
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Burden of rare variants was not different in PD patients versus controls. One PRK7 variant 
(p.R98Q) was found in four PD patients and in none of the controls. Considering PRKN, two 
different variants were identified in PD patients: a pathogenic heterozygous variant (p.R275W) 
was detected in two PD patients, MLPA excluded the presence of a second mutation. An 
additional variant of unknown significance (p.V109M) was identified in another patient. Also, a 
heterozygous variant p.A82E was identified in three controls but in none of the PD patients.
Regarding PINK1, three different variants were present in three patients and two controls. One 
patient carried the variant p.K186N, one patient and two controls had the variant p.G411S and 
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Discussion
The aim of this study was to explore the genetic variability of Estonian PD patients using a 
community-based approach. To our knowledge, this is the first report of its kind in the Baltic 
region, as there are no similar genetic studies available for Latvian and Lithuanian PD 
populations.
The present study identified a pathogenic variant frequency of 1.1% that is comparable to the 
UK´s Tracking Parkinson´s study, the largest multicentre clinico-genetic incidence study in the 
world, where a pathogenic variant frequency of 1.4% was reported.20 These low frequencies are 
interesting when considering that the general opinion is that 5-10% of PD patients have a genetic 
cause. It might be that previously described PD-linked variants do not contribute to PD in the 
Estonian cohort in the level as they contribute in other cohorts. Also, a relatively small sample 
size may set a limit to the generalizability of these results.
The most common PD associated pathogenic variant LRRK2 p.G2019S was not found in this 
study. Similarly, a recent Finnish study reported no p.G2019S point mutation in their cohort.21 It 
is known that the frequency of p.G2019S has a geographical north to south gradient and can 
range from 0% to up to 35.7% in sporadic and 42% in familial North-African Arab patients.22 In 
the Scandinavian-Baltic region, LRKK2 p.G2019S is most frequent in Norwegian PD population, 
where its overall frequency is 2.1% which rises up to 9.2% in familial cases.23 Haplotype analysis 
has revealed common founders for p.G2019S in different ethnic groups24 and a Norwegian study 
suggests that the variant was imported to Norway before the 17th century through tradesman 
from Europe.25 LRRK2 p.G2019S is also relatively common in North-Western Russian PD cohort, 
where it is present in 1.6% of all patients and in 5.3% of familial cases.26
 
LRRK2 p.E334K detected in two patients and in one control has been previously reported as a 
possible rare risk variant, however it has been thought that due to its overall low frequency more 
studies are needed to draw conclusions.27
The LRRK2 variant p.1514Q was detected in 2.1% in Estonian PD patients and 1.9% in Estonian 
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the total frequency of 2.2% in patients and 1.6% in controls, concluding that it is not linked to 
increased risk of PD.28
The LRRK2 variant p.P1542S was present at similar frequency in PD patients and controls, 
although the odds ratio compared to other Caucasian controls is slightly elevated for Estonian PD 
patients. The variant has previously been reported not to be associated with susceptibility to 
PD27, so it is possible that this variant is just more frequent in the Estonian population.
The largest number of different variants was encountered in the GBA gene. It is expected, as in 
general GBA mutations are the most common genetic risk factors for PD.29 In our study, the 
frequency of any GBA variant was 10.1% which is similar to the findings of a recent study in the 
UK.30 Interestingly, the odds ratio for any GBA variant among Estonian PD patients versus 
controls was about twice lower than in a large multinational multicentre study (OR 2.82 versus 
5.43 respectively).31 However, there are known ethnic differences also shown by the 
aforementioned study with similar odds ratios reported for example in the cohorts of National 
Human Genome Research Institute and Rostock, Germany.
The most common PD-linked GBA variants world-wide are L444P and N370S, which are present 
in approximately 15% of Ashkenazi Jewish and in 3% of non-Ashkenazi Jewish patients.31 In 
European PD patients these variants account for 70% of all mutant GBA alleles.32
Only one case of L444P (frequency of 0.5%) was found in the Estonian PD cohort and no N370S 
was detected. As GBA N370S is known to be very common among Ashkenazi Jewish patients33 
and less so in other populations, it was surprising to find just one Estonian carrier of L444P. 
When looking at the Scandinavian-Baltic region, GBA L444P appears to be the most frequent in 
Northern Sweden. A large Swedish case-control study revealed that the overall frequency of 
L444P was 2.2%, but there were significant geographical differences.34 Namely, L444P was more 
common in Northern Sweden, where it was detected in 4.11% of PD patients. Northern Sweden 
also has a higher prevalence for Gaucher´s disease.34 L444P is present in 2% of Finnish PD 
patients21 and in 1.1% of North-Western Russian PD patients.26 It remains unclear whether our 
finding is an underestimation due to a smaller cohort size or not.
8.5% of the GBA variance reported in the Estonian study is made up of GBA frequent variants 
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This study also reported a novel GBA stopgain variant p.E10x which causes haploinsufficiency 
that has recently been shown to accelerate -synuclein related pathology by altering lipid 
metabolism in a mouse model.36 
The only generally accepted VPS35 pathogenic variant to date is the point mutation p.D620N 
with a frequency of 0.1%-1% in autosomal-dominant familial PD.37,38 Therefore, it is not 
surprising that the variant was not found in the Estonian cohort. The only variant reported 
herein, p.G51S, has so far not been associated with PD.39,40
The only known PD causing variant detected in the current study was PRKN p.R275W in a 
heterozygous state in two patients. Both patients were late-onset cases and had no positive 
family history. Indeed, it is debated whether heterozygous variants in recessive genes alter the 
risk for developing PD or not.41,42,43 Furthermore, the heritability of PD is probably more complex 
than generally thought.44,45,46
An interesting finding to illustrate that is the possible autosomal-dominant behaviour with 
complete or incomplete penetrance of PINK1 variant p.G411S,47,48 A recent thorough multicentre 
case-control study provided evidence for a partial dominant-negative function of heterozygous 
p.G411S and established it as a rare genetic risk factor. The same study also speculated that 
other variants in recessive genes might increase the risk for late-onset PD over time and that the 
level of disease penetrance might be dependent on the level of mitochondrial stress.49 However, 
the role of this variant is still controversial with other reports indicating that p.G411S is likely not 
pathogenic.50
At present, other variants found in the Estonian cohort in recessive genes (PINK, PRKN, PRK7) are 
all of unknown significance.
Variants with unknown significance were reported with a frequency of 10.6% in our study. The 
frequency and role of such variants have recently been analyzed in two large independent 
cohorts.51 The analysis concluded that PD patients with a known pathogenic variant have an 
excess of additional rare variants with unknown significance compared to PD patients without a 
known pathogenic variant and controls showing that the burden of such variants might influence 
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Unfortunately, this study failed to show the same results as the burden of rare variants was not 
different between Estonian PD patients and controls and the two patients who were carrying a 
known pathogenic variant did not carry any other variant.
A low number of early onset PD cases in the current cohort explains the fact that no homozygous 
or compound heterozygous cases were found.
The strength of this study is definitely the inclusion of a broad range of patients in the 
population, regardless of their age at PD onset, family history or genetic profile. In addition, 
community-based approach can be considered as a major strength, because it helps to ensure 
genetic homogeneity among the study cohort and by that limits possible confounding 
(population stratification).
A minor limitation of the study is not having assessed systematically CNVs in recessive genes in 
all samples. Indeed, CNVs in SNCA, PRKN, PINK1, PRK7 were screened by MLPA only in early 
onset PD, PD with positive family history and carriers of heterozygous missense mutations in 
recessive genes. It is still debated whether single heterozygous CNVs are risk factors for late 
onset PD.52
While we used clear and concise definitions for pathogenic variants in present paper, the 
definition of pathogenicity remains a matter of debate. Current definitions are based on gene-
centric annotations where the causative gene or mutation is either already defined or 
predictable. However, considering the missing heritability problem, some of the pathogenic 
variants are possibly hidden in the non-coding regions of the genome where the pathogenic 
mechanisms are often elusive. These mechanisms can involve altered splicing or changed 
transcriptional efficiency and therefore are not discoverable by the gene-centric approach. We 
are still on our way to discover the functional impact of the non-coding variants. That was out of 
the scope of the present manuscript, but certainly deserves attention in our future studies.
In conclusion, this is the first PD genetic screening study in the Baltics. We have identified the 
frequencies of different genetic variants for Estonian PD patients and found an overall 
pathogenic variant frequency of 1.1%. Knowing the country-specific genetic profile of PD patients 
will be of great help in the coming future when treatments aimed at genetic targets, namely 
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Box 1. Design of the next-generation sequencing panel. 
HGNC gene symbol Inheritance Disease onset Role   
PINK1 AR Early-onset Mitochondrial function/mitophagy 
    
PRKN AR Early-onset Mitochondrial function/mitophagy; 
ubiquitination; synaptic function 
PARK7 AR Early-onset Infl ammation/immune system; 
mitochondrial function 
SNCA AD Early-onset Synaptic function; 
autophagy/lysosomal degradation; 
mitochondrial function 
LRRK2 AD Late-onset Synaptic function; 
inflammation/immune system; 
autophagy/lysosomal degradation 
VPS35 AD Late-onset Autophagy/lysosomal degradation; 
endocytosis 
DCTN1 AD NA Cell division; axonal transport 
(including autophagosomes) 
GCH1† NA NA GTP binding; calcium ion binding; BH4 
metabolism; metabolic pathways 
GBA† NA NA Inflammation/ immune system; 
autophagy/lysosomal degradation; 
metabolic pathways 
Abbreviations: HGNC, HUGO Gene Nomenclature Committee; AR, autosomal recessive; AD, 
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Table 1. Characteristics of the PD patients. 
Variable PD (n=189) 
Clinical subtype  
 Tremor-dominant (n) 43.6% (83) 
 Hypokinetic-rigid dominant (n) 5.3% (10) 
 PIGD (n) 50.8% (96) 
No family history of PD (n) 83.6 %  (158) 
1st degree relative with PD (n) 11.6%  (22) 
2nd degree relative with PD (n) 4.8% (9) 
MDS-UPDRS total score, mean (±SD) 72.8 (28.8) 
HY, median (range) 3 (1-5) 
SE-ADL, median (range) 80 (30-100) 
BDI, mean (±SD) 14.8 (7.4) 
MMSE, mean (±SD) 26.8 (3.5) 
Abbrevations: BDI, Beck Depression Inventory; HY, Hoehn and 
Yahr stage; MDS-UPDRS, Movement Disorders Society Unified 
Parkinson´s Disease Rating Scale; MMSE, Mini Mental State 
Examination; PD, Parkinson´s disease; PIGD, Postural instability 
and gait disturbance dominant; SE-ADL, Schwab and England 
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Table 2. Summary of genetic findings. 
Gene Chromosome  AA 
change 












1  0 




Risk variant 10  3 




Risk variant 6  3 
GBA 1  p.L276I Novel variant of 
unknown relevance 
1  0 
GBA 1  p.E10X Novel pathogenic 
variant 
1  0 
GCH1 14  p.V204I Likely 
pathogenic/Unknown 
relevance 
2  0 
GCH1 14  p.Q110E Unknown relevance 1  0 
LRRK2 12  p.E334K Unknown relevance 2  1 
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LRRK2 12  p.R1514Q Unknown relevance 4  3 
PRKN 6  p.V109M Unknown relevance 1  0 
PRKN 6  p.R126W Single heterozygous 
pathogenic variant 
2  0 
PRKN   p.A82E Unknown relevance 0  3 
PARK7 1  p.R98Q Unknown relevance 4  0 
PINK1 1  p.K186N Unknown relevance 1  0 
PINK1 1  p.G411S Unknown relevance 1  2 
PINK1 1  p.P209L Unknown relevance 1  0 
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Table 3. Summary of frequency of any rare variant found. 
 
Gene Prevalence in PD % 
(n) 
Prevalence in 
controls % (n) 
p-value 
GBA 10.1 (19) 3.8 (6) 0.035* 
GCH1 1.6 (3) 0 (0) 0.254 
LRRK2 3.7 (7) 2.5 (4) 0.750 
PRKN 1.6 (3) 1.9 (3) 1 
PARK7 2.1 (4) 0 (0) 0.128 
PINK1 1.6 (3) 1.3 (2) 1 
VPS35 0.5 (1) 0.6 (1) 1 
 
*Statistically significant difference 
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